Skip to main content
. Author manuscript; available in PMC: 2013 Nov 3.
Published in final edited form as: FEBS J. 2013 Feb 24;280(6):10.1111/febs.12147. doi: 10.1111/febs.12147

Fig. 4.

Fig. 4

In vivo pharmacology of SNX-5422. Effects on BT-474 tumor-bearing nude mice (n = 10) dosed with vehicle or (1) 10 mg·kg−1 SNX-5422 (SNX) by mouth three times per week, (2) trastuzumab (TZB) 3 mg·kg−1 intravenously twice per week, (3) 10 mg·kg−1 SNX by mouth three times per week and TZB 3 mg·kg−1 intravenously twice per week or (4) 40 mg·kg−1 SNX three times per week. Dosing in all drug-treated groups was for only the first 3 weeks. All groups were followed for 6 months or until sacrifice due to tumor burden. Figure reproduced from [41].